TNFRSF4 and neoplasm: To investigate the potential anti-tumor efficacy of the FAK inhibitor in combination with these antibodies, SCC6.2 cells were injected subcutaneously into FVB/N mice and mice treated with either Vehicle, Vehicle + 100 μg/mouse anti-GITR, Vehicle + 100 μg/mouse anti-CD40, Vehicle + 100 μg/mouse anti-4-1BB, Vehicle + 100 μg/mouse anti-OX40, BI 853520 + 100 μg/mouse anti-GITR, BI 853520 + 100 μg/mouse anti-CD40, BI 853520 + 100 μg/mouse anti-4-1BB or BI 853520 + 100 μg/mouse anti-OX40 (treatment schedule shown in Figure 5A).